CPA6 and epilepsy: This assumption is based on the extensive characterization of epilepsy/seizure-associated mutations in humans, which indicates that all disease-associated variants decrease the levels of CPA6 activity in the ECM in vitro, while a subset abolishes detectable expression of the mature form of the enzyme [9, 12, 13].